The European Commission approved the conditional launch of a new crown vaccine jointly developed by AstraZeneca and Oxford University on the 29th, which is the third new crown vaccine approved by the European Union.
The approval is based on the comprehensive evaluation of the safety, effectiveness and quality of the vaccine by the European drug administration, which believes that the vaccine has reliable safety, with a protection rate of 59.5% for people over 18 years old.
A total of 24000 people participated in four clinical trials conducted in the UK, Brazil and South Africa, the European Drug Administration said in the evaluation report released on the same day. All the results showed that the use of the vaccine was safe. The results of two trials showed that the vaccine was effective for people over 18 years old to prevent new crown disease, while the other two trials were not referred to due to insufficient data.